Nitroglycerin Mechanism of Action
Nitroglycerin works by converting to nitric oxide (NO), which activates guanylate cyclase to increase cyclic GMP in vascular smooth muscle, leading to vasodilation through dephosphorylation of myosin light chains 1.
Molecular Mechanism
Nitroglycerin is metabolized to free radical nitric oxide, which then:
- Activates soluble guanylate cyclase in vascular smooth muscle
- Increases cyclic GMP (guanosine 3'5' monophosphate) levels
- Causes dephosphorylation of myosin light chains, which regulate smooth muscle contraction
- Results in vascular smooth muscle relaxation and vasodilation 1
The metabolic conversion occurs primarily through mitochondrial aldehyde dehydrogenase (mtALDH), which acts as a nitrate reductase 2. This biotransformation produces 1,2-glyceryl dinitrate and nitrite as intermediates, ultimately generating NO bioactivity 2.
Hemodynamic Effects
Venous Effects (Predominant)
- Dilates capacitance vessels (venous bed), particularly in splanchnic and mesenteric circulations
- Increases venous pooling, decreasing venous return to the heart
- Reduces left ventricular preload by decreasing end-diastolic pressure and volume
- Reduces ventricular wall tension, a key determinant of myocardial oxygen demand (MVO₂) 3, 4, 1
Arterial Effects (More Modest)
- Produces arteriolar relaxation, reducing peripheral vascular resistance
- Decreases afterload by lowering systolic wall stress
- Reduces systolic, diastolic, and mean arterial blood pressure 1
Coronary Vascular Effects
- Dilates epicardial coronary arteries (both normal and atherosclerotic vessels)
- Prevents coronary vasoconstriction induced by stressors (cold, exercise, mental stress)
- Enhances collateral flow and redistributes coronary blood flow to ischemic regions
- Improves subendocardial-to-epicardial blood flow ratio
- Dilates coronary collateral vessels and reverses distal coronary vasoconstriction 3, 4, 5
Net Effect on Myocardial Oxygen Balance
The combined hemodynamic effects reduce myocardial oxygen demand while enhancing oxygen delivery, improving the myocardial oxygen supply-demand ratio 3, 4, 6:
- Decreased preload and afterload → reduced cardiac work
- Lower ventricular wall tension → decreased MVO₂
- Improved coronary perfusion → enhanced oxygen supply
- Prolonged diastole (when heart rate controlled) → increased perfusion time
Important Compensatory Response
Reflex increases in heart rate and contractility partially offset the reductions in MVO₂ 3, 4, 3. This is why concurrent beta-blocker administration is beneficial—it prevents these compensatory mechanisms that would otherwise counteract nitroglycerin's oxygen-sparing effects 3, 4.
Role as Endothelium-Independent Vasodilator
Nitroglycerin functions as an exogenous source of nitric oxide, potentially replenishing or restoring endothelium-derived relaxing factor (EDRF) activity 5. This is particularly important in patients with:
- Coronary artery atherosclerosis
- Endothelial dysfunction
- Impaired flow-mediated dilation
In these conditions, physiological vasodilation is impaired, making direct-acting vasodilators like nitroglycerin essential for achieving maximal coronary dilation 3, 4.
Additional Mechanisms
- Inhibits platelet aggregation, though the clinical significance remains unclear 3, 4, 3
- Reduces elevated central venous and pulmonary capillary wedge pressures 1
- Decreases pulmonary and systemic vascular resistance 1
Clinical Caveat on NO Formation
Research suggests a marked discrepancy between nitroglycerin's strong vasoactivity and its poor NO donor properties at therapeutic concentrations 7. Significant NO formation occurs only at suprapharmacological concentrations (>10 μmol/L), yet vasodilation and cGMP pathway activation occur at much lower doses (10-1000 nmol/L) 7. This indicates the mechanism may be more complex than simple NO donation, possibly involving direct activation of the sGC/cGMP pathway without free radical NO as an intermediate 7.